NetScientific PLC Glycotest Adds Allowed Chinese Patent to Portfolio
November 02 2017 - 3:00AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
02 November 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Glycotest(TM) Further Strengthens its Intellectual Property
Portfolio with an Allowed Chinese Patent
London, UK - 02 November 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, announces that a Chinese patent
exclusively licensed to one of its portfolio companies, Glycotest,
has been allowed. The patent provides broad protection of the
assays in Glycotest's HCC Panel test for early-stage hepatocellular
carcinoma (HCC) and the Company's pipeline tests for liver fibrosis
and other serious liver disease.
This patent expands Glycotest's existing patent portfolio which
has 10 previously granted or allowed patents, protecting multiple
aspects of Glycotest's proprietary liver disease diagnostic
platform. Glycotest now holds patents in the US, Europe, Japan and
Australia covering the use of over 50 unique glycoprotein
biomarkers and related assay technology for the diagnosis of liver
cancers and other liver diseases. These patents have been licensed
exclusively on a worldwide basis to Glycotest by Drexel University
College of Medicine and the Blumberg Institute of the Hepatitis B
Foundation.
Glycotest's lead product, HCC Panel, has demonstrated in two
studies of 208 patients and 127 patients respectively that it has
the potential to outperform the current dominant blood test (AFP)
regarding the early detection of HCC in patients with
cirrhosis.
NetScientific holds an 87.5% stake (67% on a fully diluted
basis) in Glycotest.
Commenting on the news, NetScientific's Chief Executive Officer
and Chairman of Glycotest, Francois R. Martelet said: "We are
pleased to announce that Glycotest's IP portfolio will now also
cover China, a highly significant market, which accounts for over
50% of worldwide deaths from liver cancer. We believe Glycotest's
HCC panel will enable early detection of HCC and, once
commercialised, will change the paradigm of care."
The full text of the announcement from Glycotest can be found
below.
For more information please contact:
NetScientific
François R. Martelet, M.D., CEO
Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
info@netscientific.net
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson /
Chris Welsh / Laura Thornton
Tel: +44 (0)20 3709 5700
netscientific@consilium-comms.com
Stifel Nicolaus Europe Limited (NOMAD and Broker)
Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
Glycotest Inc.
Lawrence Cohen
Office: +1 646 722 4339
larry.cohen@glycotest.com
About NetScientific:
NetScientific is an IP commercialisation group focused on
healthcare with an investment strategy focused on sourcing, funding
and commercialising technologies that significantly improve the
health and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
Glycotest(TM) Expands Patent Portfolio with Chinese Patent
New York, NY- November 02, 2017-Glycotest, Inc. announced today
that a Chinese patent covering platform technology for the assay of
its proprietary fucosylated biomarkers has been allowed.
Glycotest is a private liver disease diagnostics company
commercializing new and unique blood tests for liver cancers and
fibrosis-cirrhosis. The Company's mission is to reduce mortality
and increase survival for the growing population at risk from
serious liver diseases. Glycotest employs unique non-invasive blood
tests based on proprietary serum biomarkers, biomarker panels and
assay technology that exploit novel sugar-based disease signal
chemistry.
The Chinese patent announced today provides broad protection of
the assays in Glycotest's HCC Panel test for early-stage
hepatocellular carcinoma (HCC) as well as the Company's pipeline
tests for liver fibrosis and other serious liver disease. Included
in this patent is protection of the recombinant engineered lectin
reagents key to detection of the novel fucosylation liver disease
signal employed in all of the Company's tests. Glycotest believes
its tests can significantly reduce the burden of serious liver
disease worldwide, including parts of the world like China that are
severely affected. Over 50% of worldwide deaths from liver cancer
occur in China. The patent announced today joins 10 previously
granted or allowed patents in the United States, Europe, Japan and
Australia covering over 50 novel fucosylated protein biomarkers and
the assay technology required to measure them. These patents have
been licensed exclusively and on a worldwide basis to Glycotest by
Drexel University College of Medicine and the Blumberg Institute of
the Hepatitis B Foundation, both in the Philadelphia area.
Glycotest continues to seek further strong, broad and
geographically diverse protection of its novel liver disease
diagnostic technology through prosecution of applications pending
in commercially important US and international jurisdictions.
Glycotest's Chief Executive Officer Lawrence Cohen said, "This
patent marks Glycotest's first patent in China, an important step
toward building a strong intellectual property position in China to
support the commercialization of our HCC Panel test for early-stage
HCC and our pipeline tests for other serious liver diseases. We
expect our tests to significantly expand the number of patients
that can be identified for early therapeutic intervention,
extending and improving quality of life for many patients afflicted
with serious liver disease."
###
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company
commercializing novel clinical laboratory testing services for
patients at risk for liver cancers and fibrosis-cirrhosis. The
Company was founded in 2012 on proprietary technology that
originated at the Philadelphia area institutions Baruch S. Blumberg
Institute and Drexel University College of Medicine. Learn more at
www.glycotest.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAKMMGMZMDGNZZ
(END) Dow Jones Newswires
November 02, 2017 03:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024